EGFR and breast carcinoma: Decreased cancer cell proliferative activity has been shown in non-small cell lung cancer and breast cancer when anti-IL6 antibodies were combined with EGFR small molecule inhibitor Erlotinib and anti-Human Epidermal Growth Factor Receptor (HER2) monoclonal antibody Trastuzumab, respectively [205].